New hormone therapies and combinations are being tested to address resistance, which is when a drug stops working. Learn about emerging types of hormone therapies and explore trials studying these new drugs.
Over time, people may develop resistance to CDK4/6 inhibitors, which means the drugs stop working. Learn about new strategies being studied in clinical trials to overcome resistance.
Clinical trials are studying the response of ER low tumors to hormone therapy. Visit the links to learn more.
Read about the clinical trials that contributed to 2 recent approvals of MBC treatment options.
Click to learn about elacestrant (Orserdu) as well as the Guardant360 blood test that identifies people likely to benefit from the drug.
Learn about new CDK 4/6 inhibitor research in different breast cancer subtypes, including HER2+ and triple-negative MBC.
About 1% of BC diagnoses are male. Read more about male MBC treatment options and why male participation in clinical trials is necessary.
Click here for MBC-related research and reports from ESMO 2021.
Click here for MBC-related research and reports from ASCO 2021.
Learn about oral SERDs in clinical trials for ER+ MBC.
